英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
50607查看　50607　在百度字典中的解释百度英翻中〔查看〕
50607查看　50607　在Google字典中的解释Google英翻中〔查看〕
50607查看　50607　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Leqembi - ALZFORUM
    Lecanemab treatment stopped tangle accumulation over the course of the study, according to data presented at the 2024 AD PD conference (Mar 2024 conference news) This occurred regardless of baseline tau load In February 2024, Eisai began post-marketing tracking of lecanemab safety in Japan, where it was approved in late 2023
  • Lecanemab in Early Alzheimers Disease. | ALZFORUM
    Lecanemab’s risks of brain bleeding and swelling are real too In fact, they’re really complicated, especially in persons who are APOE4 carriers APOE4 carriers have a dose response decrement in benefit, the risk affects the very same organ the drug is treating, and an APOE result ramifies into a family
  • Finally: Big Win on All Outcomes for Lecanemab in Phase 3 . . . - ALZFORUM
    Eisai and Biogen yesterday announced positive topline results from the Phase 3 Clarity trial of their anti-amyloid antibody lecanemab The drug slowed decline on the primary endpoint, CDR-SB, by 27 percent over 18 months, and also nudged down decline on all secondary clinical endpoints The
  • Lecanemab Bested Three Other Antibodies at Binding Soluble Aβ . . .
    Four anti-amyloid antibodies—lecanemab, aducanumab, gantenerumab, donanemab—cleared plaque from the brain in Phase 3 trials, but only two went on to receive traditional U S marketing approval What distinguished the successful ones? In a preprint posted to bioRxiv on October 12, scientists led
  • Questions, Questions for Donanemab, Lecanemab - ALZFORUM
    For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they modeled how plaque clearance relates to cognitive benefit in an attempt to address a nagging question about this relationship See, You’re Negative
  • Etalanetug - ALZFORUM
    People with mild cognitive impairment or dementia will receive open-label intravenous lecanemab for 24 weeks, and then be randomized to intravenous E2814 or placebo plus lecanemab for the remainder of the four-year trial Participants with normal cognition will start on E2814 or placebo for one year, and then add open-label lecanemab
  • Leqembi in the Clinic: So Far, ARIA Echoes Trials | ALZFORUM
    The scientists reported that so far, adverse events in clinical practice resemble those in the trials In some settings, rates of ARIA-E are lower than expected, perhaps because many medical centers exclude APOE4 homozygotes In support of withholding lecanemab from this group of patients, Stefan Teipel at the German Center of Neurodegenerative Diseases, Rostock, presented a Bayesian
  • Estimating the long-term health outcomes of treatment with lecanemab in . . .
    Burn O, Molloy K, Kanekiyo M, Parker C, Rothwell S, Pan JJ, Trueman D, Ritchie C Estimating the long-term health outcomes of treatment with lecanemab in early Alzheimer's disease: a modelling study
  • Rising Leqembi Prescriptions Are Straining Clinic Capacity
    As lecanemab use ramps up, clinicians expect demand to overwhelm the staff at most memory clinics At WashU’s Knight Alzheimer Disease Research Center—one of the larger centers in the country—the staff comprises 12 physicians and four physician assistants or nurse practitioners
  • Leqembi Maintenance Dosing Approved in the U. S. | ALZFORUM
    The U S Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27 Previously, the label called for biweekly IV dosing The new decision allows physicians to consider transitioning patients to monthly dosing once they have completed





中文字典-英文字典  2005-2009